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Background: Postpartum hemorrhage (PPH) is a major cause of maternal mortality, accounting for one quarter of
all maternal deaths worldwide. Estimates of its incidence in the literature vary widely, from 3 % to 15 % of deliveries.
Uterotonics after birth are the only intervention that has been shown to be effective in preventing PPH. Tranexamic
acid (TXA), an antifibrinolytic agent, has been investigated as a potentially useful complement to uterotonics for
prevention because it has been proved to reduce blood loss in elective surgery, bleeding in trauma patients, and
menstrual blood loss. Randomized controlled trials for PPH prevention after cesarean (n = 10) and vaginal (n = 2)
deliveries show that women who received TXA had significantly less postpartum blood loss without any increase in
their rate of severe adverse effects. However, the quality of these trials was poor and they were not designed to test
the effect of TXA on the reduction of PPH incidence. Large, adequately powered, multicenter randomized controlled
trials are required before the widespread use of TXA to prevent PPH can be recommended.
Methods and design: A multicenter, double-blind, randomized controlled trial will be performed. It will involve 4000
women in labor for a planned vaginal singleton delivery, at a term≥ 35 weeks. Treatment (either TXA 1 g or placebo)
will be administered intravenously just after birth. Prophylactic oxytocin will be administered to all women. The primary
outcome will be the incidence of PPH, defined by blood loss ≥500 mL, measured with a graduated collector bag. This
study will have 80 % power to show a 30 % reduction in the incidence of PPH, from 10.0 % to 7.0 %.
Discussion: In addition to prophylactic uterotonic administration, a complementary component of the management
of third stage of labor acting on the coagulation process may be useful in preventing PPH. TXA is a promising
candidate drug, inexpensive, easy to administer, and simple to add to the routine management of deliveries in
hospitals. This large, adequately powered, multicenter, randomized placebo-controlled trial seeks to determine if
the risk-benefit ratio favors the routine use of TXA after delivery to prevent PPH.
Trial registration: ClinicalTrials.gov NCT02302456 (November 17, 2014)
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Rational
Active management of the third stage of labor for the
prevention of postpartum hemorrhage
Postpartum hemorrhage (PPH) is classically defined as
blood loss of 500 mL or more after delivery [1]. Esti-
mates of its incidence in the literature vary widely, from
3 % to 15 % of deliveries [2–5]. About one in five of
these hemorrhages progresses to a severe form that may
endanger the mother’s life or at least her future fertility
and exposes her to the risks of transfusion, surgery, and
intensive care. PPH remains a leading cause of maternal
mortality and accounts for about one quarter of all mater-
nal deaths worldwide. Its risk factors include previous
PPH, primiparity, obesity, prolonged or augmented labor,
multiple pregnancy, previous cesarean delivery, polyhy-
dramnios, and macrosomia [4, 5]. Nevertheless, most
women with PPH have low-risk pregnancies and no iden-
tifiable risk factors [6, 7]. It is therefore essential to prevent
PPH in all women [8–11].
Because placental expulsion is a critical window for
the prevention of PPH, various preventive interventions
during this stage have been proposed. They can be sche-
matically divided into two categories: those involving a
mechanical mechanism, and those involving prohemo-
static agents. Active management of the third stage of
labor (AMTSL) comprises a combination of mechanical
interventions: preventive administration of uterotonic
agents immediately after delivery of the child, early cord
clamping and cutting, controlled cord traction (CCT),
and, according to some authors, uterine massage [12].
Nevertheless, it has been clearly shown that the adminis-
tration of uterotonics, and in particular oxytocin, after
birth is the only component of AMTSL that is effective
in preventing PPH [13–17]. However, in addition to this
enhancement of mechanical hemostasis, a complemen-
tary biochemical hemostatic effect might be expected
from the complementary use of prohemostatic drugs
such as tranexamic acid.
Tranexamic acid for the reduction of bleeding in medical
contexts other than PPH
Tranexamic acid (TXA) is a potent antifibrinolytic agent
that exerts its effect by blocking lysine binding sites on
plasminogen molecules and has the potential to enhance
the effectiveness of the patient’s own hemostatic mecha-
nisms. Consequently, clot breakdown (fibrinolysis) is inhib-
ited and bleeding is reduced [18]. Results from previous
trials have shown that TXA in planned surgery reduces the
risk of blood transfusion, mean transfused volume, and
need for re-operation due to bleeding, without increasing
thrombotic events [19, 20]. The CRASH-2 trial (Clinical
Randomisation of an Antifibrinolytic in Significant Haem-
orrhage) demonstrated that the administration of TXAreduced mortality in bleeding trauma patients in high-,
middle-, and low-income countries [21]. Significant reduc-
tions in mean menstrual blood loss have been reported in
women with menorrhagia treated with TXA, compared
with control or placebo-treated women [22]. This result is
particularly significant since the efficacy of TXA in menor-
rhagia suggests that it can reduce uterine blood loss, even
of low volume, and in a nonsurgical context [23].
Tranexamic acid for PPH
During delivery, when the placenta separates from the
uterine wall, sequential physiologic and hemostatic
changes occur and reduce bleeding, including strong
myometrial contractions, increased platelet activity, and
a massive release of coagulant factors; at the same time,
however, fibrinolytic activity increases [24]. While oxyto-
cin administration enhances the first mechanism, TXA
administration might be able to counter the latter and
thus facilitate the hemostatic process. Finally, the close
relation observed between reduced fibrinogen levels and
outcome in cases of PPH [25, 26] further suggests that
TXA might be effective in PPH [27].
Treatment of PPH The only randomized controlled
trial (multicenter open-label trial) to assess TXA for the
treatment of PPH showed that a high dose of TXA
reduces blood loss in women with PPH [27]. Due to its
limitations (small sample size, open design, issues re-
garding the harm-benefit ratio), and conflicting results
from a before-and-after study using the same protocol
[28], the use of TXA to treat PPH remains the object of
debate. A pragmatic, randomized, double-blinded, placebo-
controlled trial in women with a clinical diagnosis of PPH,
the WOMAN trial, has been launched to rectify this clin-
ical uncertainty [29]. It is currently recruiting eligible
women in hospitals in Africa and Europe, aiming to reach
the target sample size of 15 000 women [29].
Prevention of PPH A Cochrane systematic review pub-
lished in 2011 examined the use of TXA to prevent
PPH. It identified 5 RCTs and included 2 of them in the
meta-analysis, which covered a total of 453 women [18].
The authors concluded that the available evidence, al-
though it suggested that TXA decreases postpartum
blood loss, was of unclear quality and that further inves-
tigation was needed. Several additional trials have been
published since then.
Through a Medline search up to March 1, 2014, we
identified 12 RCTs that have assessed this issue (Tables 1
and 2) [30–41]. All were performed in low-or middle-
income countries (China, India, Iran, Turkey, Pakistan,
and Egypt). All but two [40, 41] only included women
with cesarean deliveries. Overall, the quality of these tri-
als was poor. Selection, performance, and detection bias
Table 1 Characteristics of the randomized trials that have assessed tranexamic acid for preventing postpartum hemorrhage after cesarean delivery
Study [réf] Country Study design Sample size Study groups Intervention TXA Dosage/
route
Primary outcome Result P value Adverse effects
Gai et al. al, (2004) [30] China Multicenter, prospective,
randomized controlled
study
N = 180,
primiparas
N = 91
(experimental)
Infusion of
TXA 10 min
before CS
1 g IV for
5 min
Postpartum
blood loss not
clearly specified
359.3 mL vs
439.3 mL
0.002 No thromboembolic or
other side effects
reported
N = 89 (no
placebo)
Gohel et al., (2007) [31] India Prospective, randomized
controlled study
N = 100,
primiparas
and
multiparas
N = 50
(experimental)
Infusion of
TXA 20 min
before CS
1 g IV for
5 min
Postpartum
blood loss not
clearly specified
374.9 mL vs
472.8 mL
0.003 No thromboembolic
or other side effects
reported
N = 50 (no
placebo)
Sekhavat et al., (2009) [32] Iran Prospective, randomized,
placebo-controlled study
N = 90,
primiparas
N = 45
(experimental)
Infusion of
TXA 10 min
before CS
1 g IV for
5 min
Postpartum
blood loss not
clearly specific
28.0 mL vs
37.1 mL
0.001 No thromboembolic
or other side effects
reported
N = 45
(placebo)
Gungorkuk et al., (2011) [33] Turkey Prospective, unicenter,
double-blind, randomised
controlled study
N = 666,
primiparas
and
multiparas
N = 330
(experimental)
Infusion of
TXA 10 min
before CS
1 g IV for
5 min
Estimated blood
loss during CS.
600.7 mL vs
499.9 mL
<0.001 Gastrointestinal side
effects (16.3 %) in the
experimental group
N = 330
(placebo) Gastrointestinal side
effects not mentioned
for the placebo group.
No thromboembolic
events
Movafegh et al., 2011 [34] Iran Prospective, unicenter,
double-blind, randomized
controlled study
N = 100,
primiparas
and
multiparas
N = 50
(experimental)
Infusion of
TXA 20 min
before CS
10 mg/kg IV
for 10 min
Postpartum
blood loss not
clearly specified
262.5 mL vs
404.7 mL
<0.001 No thromboembolic
events
N = 50
(placebo)
Xu et al., 2013 [35] China Randomized, double-blind,
placebo-controlled study
N = 174
primiparas
N = 88
(experimental)
Infusion of
TXA 10 min
before CS
10 mg/kg IV
for 5 min
Postpartum
blood loss not
clearly specified
379 mL vs
441 mL
0.02 2 thromboses occurred
in each group.
Gastrointestinal side
effects occurred in 10
TXA patients versus
one placebo patient
N = 86
(placebo)
Senturk et al., 2013 [36] Turkey Randomized, double-blind,
placebo-controlled study
N = 223,
primiparas
and
multiparas
N = 101
(experimental)
Infusion of
TXA 10 min
before CS
10 mg/kg IV
for 5 min
Postpartum
blood loss not
clearly specified
272 mL vs
347 mL
0.001 No thromboembolic or
gastrointestinal side
effects
N = 122
(placebo)
Shahid A et al., 2013 [37] Pakistan Randomized double-blind
placebo controlled study
N = 74
primiparas
and
multiparas
N = 38
(experimental)
Infusion of
TXA 10 min
before CS
1 g IV for
10 min
Postpartum
blood loss not
clearly specified
356 mL vs
710 mL
<0.001 No thromboembolic
side effects
N = 36
(placebo)
Abdel-Aleem et al., 2013
[38]
Egypt Randomized, single center,
open, controlled study
N = 740
primiparas
N = 373
(experimental)
1 g IV for
10 min
241.6 mL vs
510.6 mL
<0.001
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Table 1 Characteristics of the randomized trials that have assessed tranexamic acid for preventing postpartum hemorrhage after cesarean delivery (Continued)
and
multiparas
Infusion of
TXA 10 min
before CS
Blood loss two
hours after
delivery
Gastrointestinal side
effects (74.3 % versus
53.1 %; P = 0.0001)
N = 367 (no
placebo)
No thromboembolic
side effects
Goswami et al., 2013 [39] India Randomized, single center,
double-blinded placebo
controlled study
N = 90
primiparas
and
multiparas
N = 30
(experimental
1)
Infusion of
TXA 20 min
before CS
Experimental
1: 10 mg/kg
Postpartum
blood loss, not
clearly specified
376.8 mL vs
261.2 mL vs
527.2 mL
Not
reported
No thromboembolic
side effects
N = 30
(experimental
2)
Experimental
2: 15 mg/kg
N = 30
(placebo)
TXA Tranexamic acid, IV intravenous
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Table 2 Characteristics of the randomized trials that have assessed tranexamic acid for preventing postpartum hemorrhage after vaginal delivery
Study [réf] Country Study design Sample size Study groups Interventions TXA
Dosage/
route
Primary outcome Result P value Adverse effects
Yang et al.,
(2001) [40]
China Multicenter, randomized
controlled study
N = 400
primiparas
N = 94
(experimental 1)
Infusion of TXA after
delivery of the fetal
shoulders in the first
2 groups and infusion
of AMBA in the third
1 g IV. Measurement of blood
loss 2 h after delivery,
without details about
the measurement method
243.3 mL vs
242.9 mL vs
308.1 mL vs
314.8 mL
<0.01 Nausea (n = 2)
0.5 g IV
N = 92
(experimental
2)
N = 92
(experimental
3)
0.5 g IV
N = 87 (no
placebo)
placebo
Gungorkuk
et al.,
(2013) [41]
Turkey Prospective, single-center,
double-blinded, randomized
controlled study
N = 439
primiparas
and
multiparas
N = 220
(experimental)
N = 219
(placebo)
Infusion of TXA at
delivery of the
anterior shoulder
1 g IV
for
5 min
Mean blood loss during the
third and fourth stages of
labor - from the end of
delivery to 2 h postpartum-
measured as (weight of
material used – weight of
materials before use)/1.05
261.5 mL vs
349.9 mL
<0.001 Gastrointestinal
side effects
(35.9 %)
No
thromboembolic
event
TXA Tranexamic acid, AMBA aminomethylbenzoic acid, IV intravenous
Sentilhes
et
al.BM
C
Pregnancy
and
Childbirth
 (2015) 15:135 
Page
5
of
13
Sentilhes et al. BMC Pregnancy and Childbirth  (2015) 15:135 Page 6 of 13might have influenced their results; in particular, the pri-
mary outcome was never the incidence of either PPH or
severe PPH but rather other indicators of blood loss that
may not be clinically relevant. The method used to
measure the primary outcome based on estimated blood
loss was often imprecise and subject to both perform-
ance and detection bias. These flaws mandate a cautious
interpretation of their results [18, 42].
We found 10 published RCTs evaluating the efficacy
of TXA in preventing PPH after cesarean delivery [30–
39]. Their characteristics are summarized in Table 1. In
all but one of these studies [36], the cesareans were
elective. These 10 RCTs all reported a significantly
smaller mean postpartum blood loss in women who had
received TXA, and no detectable adverse effect on their
primary vital signs (blood pressure, heart rate, and re-
spiratory rate) or thrombosis (Table 1) [30–39]. Never-
theless, it is important to emphasize that most of these
RCTs have various methodological flaws and included
small samples with inadequate power to assess the risk
of adverse effects.
Only 2 trials evaluated the efficacy of TXA for the pre-
vention of PPH after vaginal delivery [40, 41] (Table 2).
In 2001, Yang al. reported a RCT comparing four groups
[26]. One group (n = 94) received a single dose of 1 g
TXA by intravenous infusion (IV), and another group
(n = 92) a single dose of 0.5 g TXA, also IV. The third
group (n =92) received a single dose of 0.5 g amino-
methylbenzoic acid IV, and the fourth group (n = 87)
served as the control group [26]. Defining PPH as blood
loss ≥ 400 mL, the authors reported that its incidence was
lower in the women receiving the larger TXA dose (6/94)
than the control group (22/87) (Table 2). The pooled rela-
tive risk of PPH was thus RR = 0.44 (95 % CI: 0.31 to 0.64)
[26, 34]. The main limitation of this study is the absence
of placebo and blinding. Moreover, the randomization
method was not described.
More recently, Gundorkuk et al. recruited 439 women
with vaginal deliveries in a double-blinded RCT [41]
(Table 2). Women in the intervention group received a
single dose of 1.0 g of TXA IV at delivery of the anterior
shoulder, and those in the control group a placebo. The
primary outcome was the mean estimated blood loss
during the third and fourth stages of labor. It was signifi-
cantly lower in the TXA group than in the placebo group
(261.5 ± 146.8 mL compared with 349.98 ± 188.85 mL,
P <0.001). The incidence of PPH >500 mL was also
lower in the TXA group (n = 4, 1.8 %) than in the con-
trol group (n = 15, 6.8 %); RR 3.76; 95 % CI: 1.27 to
1.15, P = 0.01) [41]. Moreover, the rate of total blood
loss of at least 1000 mL was higher among women who
received placebo (2.3 %) than among women given
TXA (0.5 %), but the difference was not statistically
significant (RR 5.02, CI: 0.59 to 42.64, P = 0.12). Thegroups did not differ significantly in their need for blood
transfusion. Predelivery hemoglobin and hematocrit levels
were the same in both groups, but the day after delivery,
both hemoglobin (9.9 ± 1.4 g/dL and 9.3 ± 0.9 g/dL, P <
0.001) and hematocrit levels (30.2 % ± 1.2 % and 29.0 ±
1.3, P < 0.001) were higher in the TXA than the placebo
group [41]. Finally, no episodes of thrombosis occurred in
the women who received TXA. The results of this single-
center trial suggest that TXA is a promising drug for the
prevention of PPH after vaginal delivery and possibly
for the reduction of maternal morbidity related to PPH.
Nevertheless, there are again some concerns about the
external validity of these results observed in a middle-
income country, partly because it was a single-center
study and, relatedly, because it was underpowered to
assess severe adverse events.
Severe maternal adverse events related to tranexamic acid
Caution is necessary before recommending the use of
this drug in routine practice for prevention or treatment
of PPH, in view of the number of eligible women who
would be eligible to receive it in both cases: not only is
the evidence supporting its efficacy still insufficient, but
also and especially the number of venous and arterial
thrombotic events might increase after its administra-
tion. Consequently, until now, no authorities or learned
societies have recommended the administration of TXA
to prevent PPH, after either vaginal or cesarean delivery.
Because TXA inhibits fibrinolysis, it carries a potential
risk of thrombosis, especially in patients with a previous
history of thrombosis and in pregnant women. Never-
theless, the systematic review of randomized controlled
trials of elective surgical patients cited above (129 ran-
domized controlled trials including 10 488 randomized
participants, 5484 of them allocated to TXA) showed no
significant increases in the incidence of myocardial in-
farction, stroke, deep vein thrombosis, or pulmonary
embolism [20]. Moreover, the CRASH-2 trial of TXA in
bleeding trauma patients showed a statistically signifi-
cant reduction in global mortality with no increase in
thromboembolic events [21]. Nevertheless, as thrombo-
embolic events are relatively rare, these trials do not re-
solve the uncertainties about this risk because most of
these trials lacked the statistical power to detect clinic-
ally important increases in risk. In particular, five cases
of acute renal failure due to thrombosis-induced cortical
necrosis following TXA administration have been de-
scribed [43–47].
The evidence available for assessing the safety of TXA
use in parturients for prevention of PPH is even more
limited than for nonpregnant patients, given the limited
number of such women thus far enrolled in TXA trials
and the expected incidence of these adverse events. It is
well known that the risk of venous thromboembolism
Sentilhes et al. BMC Pregnancy and Childbirth  (2015) 15:135 Page 7 of 13increases during normal pregnancy and especially during
the first 6 weeks postpartum [48]. It is nonetheless im-
portant to underline that no significant increase in the
incidence of thrombotic events related to TXA has been
observed in any trials of TXA among pregnant women
(n = 2228), including RCTs, observational nonrando-
mized studies and case series [49].
In conclusion, TXA appears to be a promising drug
for the prevention of PPH, but the results currently
available are too limited to justify its widespread use.
Given the current uncertainty regarding both its efficacy
and its adverse effects in parturient women, we propose
to perform an adequately powered, multicenter, random-
ized, placebo-controlled trial to determine the impact of
systematic TXA administration after vaginal delivery on
PPH incidence. If TXA is effective, its routine use should
reduce the incidence of PPH among women with vaginal
deliveries. If TXA is shown to be ineffective, this will
prevent the diffusion of an ineffective medication associ-
ated with potential adverse effects in routine practice.
The hypothesis is that a low dose of TXA (1 g) after
vaginal delivery, administered in the 2 min after the
child’s delivery and after prophylactic oxytocin adminis-
tration, reduces both blood loss and the incidence of
PPH and its complications.
Objectives
The aim of this study is to compare the effect of a low
dose of TXA (1 g) after vaginal delivery in the 2 min
after the child’s delivery and after prophylactic oxytocin
administration, versus placebo with prophylactic oxyto-
cin in a multicenter randomized, double-blind, placebo-
controlled trial.
The specific objectives are as follows:
 To assess the impact of TXA (1 g) after vaginal
delivery on postpartum blood loss
■ Primary outcome
➢Incidence of PPH, defined by blood loss ≥
500 mL, measured with a graduated collector bag■ Secondary outcomes
➢Other outcome measures describing
postpartum blood loss, such as mean measured
total postpartum blood loss, incidence of severe
PPH, defined by blood loss ≥ 1000 mL, proportion
of women requiring supplementary uterotonic
agent, transfusion, arterial embolization, or
emergency surgery for PPH, and mean
peripartum change in hemoglobin and hematocrit
 To assess the potential adverse effects of TXA (1 g)
after vaginal delivery:
■ The hemodynamic parameters, gastrointestinal
side effects, renal, hepatic and coagulationfunction, venous or arterial thrombosis within
3 months following delivery.
 To assess women’s satisfaction and psychological
status at D60Methods and design
Recruitment and allocation
Inclusion criteria
 Age ≥ 18 years
 Planned vaginal delivery
 Term ≥ 35 weeks of gestation
 Singleton pregnancy
 Informed consent form signedExclusion criteria
 History of venous (deep vein thrombosis and/or
pulmonary embolism) or arterial (angina pectoris,
myocardial infarction, stroke) thrombosis
 History of epilepsy or seizure
 Any known cardiovascular, renal, or liver disorders
 Autoimmune disease
 Sickle cell disease
 Severe hemorrhagic disease
 Placenta previa
 Abnormally invasive placenta (placenta accreta/
increta/percreta)
 Abruptio placentae
 Eclampsia, HELLP syndrome
 Multiple pregnancy
 In utero fetal death
 Administration of low-molecular-weight heparin or
antiplatelet agents during the week before delivery
 Poor understanding of the French language
Individual information on the trial will be provided to
women in late pregnancy by obstetricians and midwives
during prenatal visits or by anesthetists during the sys-
tematic anesthesia visit, or both. This information will
be repeated when the women arrive in the delivery
room; each woman will then confirm her participation
and provide informed written consent before delivery,
when, in the investigator’s opinion once she has reached
at least 4 cm of cervical dilatation, she is likely to have a
vaginal delivery.
The randomization will be centralized and stratified by
center and balanced in blocks of variable sizes. Once a
woman has been included, through the filing of an elec-
tronic case report directly by internet (Clinsight soft-
ware), she will retain her randomization number (if it
has been assigned to her) even if she withdraws from the
study or refuses randomization afterwards.
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(Sanofi Aventis, Paris, France; Marketing authorization
number: 3400931157618 [1974, RCP rév 02.04.2010])
or placebo (normal saline, Fresenius Kabi, Sèvres,
France; Marketing authorization number: 34009415
73941). The Angers Clinical Research Unit will create
the randomization list for allocations to the TXA and
control groups. This list will be transmitted to the
pharmacy department of CHU Angers, which belongs
to the PPRIGO hospital pharmacists’ consortium (Pro-
duction Pharmaceutique pour la Recherche Institu-
tionnelle du Grand Ouest). The blinded products will
be prepared by the Angers CHU pharmacy according
to GMP for hospital pharmacies (BPP 2007), which
will provide numbered and labeled boxes, each con-
taining a 10-mL vial of the study drug (1 g of TXA or
placebo according to the randomization number). All
boxes and vials will be identically labeled, with the
study number being the only differentiating feature
between different drug packs. This will ensure the
woman’s safety and the blinding of all participants, in-
cluding obstetric staff.
Intervention
The intervention will be the intravenous administration
of a 10-mL blinded vial of the study drug (either 1 g of
TXA or placebo, according to the randomization group),
slowly (over 30–60 sec), in the 2 min after birth and the
routine prophylactic oxytocin, and after the cord has
been clamped, all generally by the midwife (but some-
times by the anesthesiologist or obstetrician, depending
on availability).
Except for the content of the study drug vial, all as-
pects of management of the third stage will be identical
in both arms:
 Routine prophylactic intravenous injection of 5 IU
oxytocin at delivery of the anterior shoulder or within
2 min of birth, as recommended in the national
clinical practice guidelines issued by the French
College of Gynecologists and Obstetricians [50].
 Placement of a graduated (100 mL graduation)
collector bag just after birth, left in place for at least
15 min and then until the birth attendant judges
that bleeding has stopped. When a woman is
included in the trial, a bag will be prepared and
ready to be put in place as soon as the baby is born
and placed on the mother’s belly; if needed, a second
staff person will be present to help in managing
both the baby and the bag. This will make it possible
to collect and measure vaginal blood loss objectively
during the immediate postpartum [14].
 Manual removal of the placenta at 30 min after
birth if not expelled, in the absence of bleeding. Rapid suturing of the episiotomy, in accordance with
good clinical practices.
 Systematic use of uterotonic drugs after the third
stage of labor is not recommended.
 Controlled cord traction (CCT) will be left to the
discretion of the practitioner since its use in the
management of placental expulsion has been shown
to have no significant effect on the incidence of PPH
or other markers of postpartum blood loss [14].
If PPH occurs, standardized management will be pro-
vided according to the department’s protocol. In particu-
lar, the use of TXA for the treatment of PPH will be
allowed and left to the discretion of the practitioner, ac-
cording to the department’s protocol.
Before inclusions begin, a meeting will be organized in
each maternity unit to verify the attendants’ agreement
to and understanding of the protocol and their ease in
practicing the relevant procedures.
Outcome measures
Primary outcome measure
The primary outcome of the trial is the incidence of
PPH, defined by blood loss ≥ 500 mL, measured with a
graduated collector bag. The term “measured” implies
an objective determination of the blood volume lost, in
contrast to a simple visual estimate, which has been
shown unreliable in several studies [14, 51–55].
The systematic use of a graduated collector bag for
blood, placed under the woman’s buttocks just after de-
livery of the child, will allow an objective measurement
of the blood lost through the vagina in the immediate
postpartum period.
The practical feasibility of the use of such a bag was
shown in the TRACOR trial [14]. This bag shall be left in
place for at least 15 min and afterwards until the birth at-
tendant is no longer concerned about blood loss, and
judges that the woman’s condition allows her to stretch out.
This criterion will be measured during the immediate post-
partum surveillance in the delivery room, in both groups.
Secondary outcomes
 Secondary outcome measures describing postpartum
blood loss
Clinical
– mean measured blood loss at 15 min after birth (the
collector bag must be left in place at least 15 min to
have one measure of blood loss at the same time
point for all women)
– mean measured total postpartum blood loss (at bag
removal)
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loss ≥ 1000 mL.
– proportion of women requiring supplementary
uterotonic treatment, including sulprostone
– incidence of postpartum transfusion (until discharge)
– incidence of arterial embolization and emergency
surgery for PPH.
Laboratory
– mean change in peripartum hemoglobin (difference
between Hb before delivery and at D2)
– mean change in peripartum hematocrit (difference
between Ht before delivery and on D2).
For both indicators, the pre-delivery reference examin-
ation will be the last routine blood count in the last tri-
mester of the pregnancy. A blood sample will be taken
from all women included in the trial on the second day
postpartum for the measurement of peripartum Hb and
Ht and the calculation of the change in these two indica-
tors. If no blood sample is available from D2, measure-
ment of postpartum Hb and Ht will be assessed from a D3
blood sample, if available. If no blood sample is available
from D2 or D3, measurement of postpartum Hb and Ht
will be assessed from a D1 blood sample, if available.
 The occurrence of potential adverse effects of TXA:
Clinical
– Hemodynamic parameters (heart rate, blood
pressure) 15, 30, 45, 60 and 120 min after delivery.
– the occurrence of potential mild adverse effects of
TXA in the delivery room:■ nausea
■ vomiting
■ phosphenes
■ dizziness
– the occurrence of potential severe adverse effects of
TXA up to three months of postpartum:■ deep vein thrombosis, if the diagnosis is
confirmed by Doppler ultrasound
■ pulmonary embolism, if the diagnosis is
confirmed by radiological examinations.
■ myocardial infarction
■ seizure
■ renal failure needing dialysis
■ any other unexpected adverse events.
These events will be checked by the medical team dur-
ing the hospitalization and then on D90 by a telephoneinterview of each woman. In the event that the woman
cannot be reached, at least 10 calls at different hours
over the course of the week will be made to minimize
loss to follow-up. In cases of severe adverse effects re-
ported by a woman after the hospital discharge, objective
data will be collected from medical files, transmitted ei-
ther by the woman herself or her general practitioner.
Laboratory
– urea and creatinemia, prothrombin time (PT), active
prothrombin time (aPTT), aspartate and alanine
transaminase, and total bilirubin at D2 Women’s satisfaction and psychological status– These will be assessed by a self-administered
questionnaire on day 2 postpartum and by mail on
day 60.
Statistical analysis
Data analysis and reporting will follow the CONSORT
guidelines for randomized controlled trials and will be
conducted with the trial statistician and researchers
blinded to group status. The two groups will be com-
pared for women’s demographic characteristics and
standard risk factors for PPH. Then we will seek, in an
intention-to-treat analysis, the existence of a “TXA ef-
fect”, that is, a difference between the two groups for the
primary outcome measure and the secondary outcome
measures. For secondary outcomes that are available for
women who had a cesarean delivery after randomization
(percentage of women requiring supplementary utero-
tonic agents, mean change in peripartum hemoglobin,
mean change in peripartum hematocrit, incidence of
postpartum transfusion, arterial embolization, and emer-
gency surgery), a secondary analysis will be conducted
that includes these women. The comparisons will use
nonparametric statistical tests when required by the con-
straints of population size or distributions. Comparisons
of the categorical variables will use chi2 and Fisher exact
tests, as appropriate. We will use analysis of variance
and Kruskal and Wallis’s nonparametric test for the con-
tinuous variables. Effects will be measured as relative
risks, with their 95 % confidence intervals.
The analysis plan includes an intermediate statistical
analysis when half of the planned women have been in-
cluded to ensure there is no significant difference in the
adverse events between the two groups.
Feasibility
The majority of the participating centers have previously
worked together in a French multicenter randomized con-
trolled trial that aimed to assess the effect of controlled
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trial) [17]. During a one-year period, they together ran-
domized 4068 women with vaginal deliveries and demon-
strated their capacity to conduct and perform a RCT
regarding the prevention of PPH. Moreover, all the partici-
pating centers belong to the GROG (Groupe de Recherche
en Obstétrique et Gynécologie) national network.
Sample size
In the recent RCT (TRACOR trial), involving the same
participating centers, mentioned above, comparison of
the efficacy of the controlled cord traction and standard
placenta expulsion in preventing PPH showed that the
PPH rate (measured postpartum blood loss of 500 mL
or more) was 10.0 % (402/4013), with no significant het-
erogeneity between centers [14].
Accordingly, for this study, we assumed a 10 % inci-
dence of PPH in the absence of TXA. To show a relative
reduction of at least 30 % in this incidence in the TXA
arm—that is, an incidence of 7 % or less in this arm,
with a = 0.05, 1-ß = 0.90, and a bilateral test, the study
requires 1814 women with vaginal deliveries in each
group. Given the expected proportion of women with a
cesarean delivery in labor after randomization (estimated
at 5 % to 10 % [6.8 % in the TRACOR trial] [14]), the
total number of randomized women will be greater in
order to include the needed number of women with va-
ginal deliveries: 2000 women will be included in each
group, for a total of 4000 participants.
Timetable
The participating maternity units deliver 21,500 infants
a year. We consider that 70 % of women will meet the
criteria for inclusion in the participating maternity units,
excluding scheduled cesareans, cesareans in early labor,
deliveries before 35 weeks, and multiple pregnancies.
We add to these categories the cesareans decided at the
end of labor (about 5 % of deliveries), after inclusion but
for which no primary outcome measure will be available,
and which therefore cannot be included in the analysis
— even for intention to treat. Overall, 13,975 annual de-
liveries (65 % of the total) may possibly be included in
the principal analysis. An inclusion period of 20 months
should make it possible to recruit 4,000 women, if we
assume a participation rate of at least 17.2 %. This par-
ticipation rate appears realistic in light of the recruit-
ment in the TRACOR trial in the labor wards of all the
participating centers [17].
The total duration of the trial will be 23 months, includ-
ing 20 months of inclusion and 3 months of follow-up in
the postpartum period (assessment of thromboembolic
and any unexpected adverse events).
The total duration of the project will be 34 months,
including:– 6 months for ethics approval, signatures of
agreements between the participating centers and
training the staff in the management methods
required by the protocol for the third stage of labor.
– 23 months for the trial, with an inclusion period of
16 months and a follow-up period of 3 months.
– 5 months after the end of the inclusion period will
be devoted to finalizing the data collection and
entry, database cleaning, and analysis.Ethics committee approval
This study was approved by the West II Committee for
the Protection of Research Subjects (Ethics Committee)
on August 21, 2014 (2014/09), and by the French Health
Products Safety Agency (ANSM) on August 6, 2014
(2014-001748-39).Data management
Each investigator will be responsible for ensuring data,
which will be completed by the clinical research techni-
cian throughout the trial, with Clinsight software. The
electronic case report file for each woman will contain 5
components:
– 1 completed by the clinical research technician from
the obstetric file: woman’s characteristics, course of
the pregnancy, labor, and delivery
– 1 completed by the clinical research technician about
the postpartum events after leaving the delivery room,
and the results of the blood count on D2
– 1 questionnaire about women’s satisfaction on D2
postpartum, completed by the women, with
responses entered secondarily in the electronic file
by the clinical research technician.
– 1 questionnaire about the women’s satisfaction and
psychological status on D60 postpartum, sent by the
technician to the women and completed by them,
with responses entered secondarily in the electronic
file by the clinical research technician.
– 1 questionnaire about the occurrence of
thromboembolic and any other unexpected events at
12 weeks in postpartum, completed by the clinical
research technician during a telephone interview
with the woman, with responses secondarily entered
in the electronic file by the technician.
Data will be collected for women who have a cesarean
delivery after randomization, data will be collected.
The data management and statistical aspects will be
handled centrally by the Angers University Hospital (De-
partment of Clinical Research and Development - Meth-
odology and Biostatistics Unit) with the Scientific Director
of the study (CDT).
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standard operating procedures of the sponsor, Angers
University Hospital. The research in the investigational
centers and management of subjects will comply with
the Declaration of Helsinki and Good Clinical Practices.
An independent data monitoring committee including
only independent members will be in charge of control-
ling the quality and the safety of the trial procedures and
of the data collected. Clinical research assistants will
conduct monthly visits in each investigative center and
report to the data monitoring committee. During these
onsite inspections and in accordance with Good Clinical
Practices, the following items will be reviewed:
– Compliance with the research protocol and the
procedures defined therein
– Verification of the patients’ informed consents, for
all women included
– Examination of the source documents and their
comparison with the data reported in the electronic
case report files (CRFs), for the accuracy and
consistency of the data and the missing data,
performed on a random sample of 10 % of
participating women.
– End-of-trial visit: archiving of research documents.
Trial steering committee
A trial steering committee will be set up which will have
overall supervision of the trial. It will meet before the
trial starts and then at least every 6 months until com-
pletion. A meeting of the TSC will be held within a
month of every Safety Monitoring Committee meeting
to consider their recommendations.
Safety consideration
An independent Safety Monitoring Committee will also
be formed. They will meet at minimum yearly to examine
recruitment figures, baseline data, retention and adverse
events. The Safety Monitoring Committee will review the
result of the interim analysis of safety data when half of
the planned participants have been recruited.
Suspected unexpected serious adverse reactions (SUS-
ARs) will be recorded and reported using the ANSM ap-
proved SUSAR form. SUSARs include maternal death,
surgery (other than cesarean delivery) in the 12 weeks
following randomization, transfusion of more than 4
units of blood, admission to an intensive care unit, deep
vein thrombosis, pulmonary embolism, myocardial in-
farction, seizure, renal failure defined by the need for
dialysis, or suspected drug reactions. In the event of a
SUSAR the form will be completed by the local trial co-
ordinator and faxed to the trial coordinating center at
the Angers University Hospital within 72 h. From there
the copies of the form will be sent to the trial statisticianand the chair of the Safety Monitoring Committee. The
Safety Monitoring Committee will have the power to ask
to break the blinding, whereas the study investigators
will remain blinded to the allocated treatment. The
ANSM, the trial sponsor and the Chair of the Ethics
Committee will also be informed by the Safety Monitor-
ing Committee if considered appropriate, in particular in
cases of strong suspicion of SUSARS related to the In-
vestigational Medicinal Products. Finally, should the
Safety Monitoring Committee believe it necessary, it is
authorized to recommend, to the Scientific Committee
that the trial be stopped.Discussion
Potential and implementation of the findings
In addition to prophylactic uterotonic administration, a
complementary component of the management of third
stage of labor that acts on the coagulation process may
be useful for PPH prevention. This prevention is especially
important as several reports from various high-resource
countries describe recent increases in PPH incidence [3,
56, 57]. TXA is a promising candidate drug, inexpensive
and easy to administer, that could be added to the routine
delivery management of all women in hospitals worldwide.
The evidence currently available is too limited to justify its
widespread use for PPH prevention. This large, adequately
powered, multicenter, randomized placebo-controlled trial
aims to determine if the risk-benefit ratio favors the sys-
tematic use of TXA after delivery to prevent PPH.Dissemination
A final report will be prepared for the funding body, and
papers will be prepared for peer-review publication and
national/international dissemination.Conclusion
Both theoretical arguments and results from RCTs con-
ducted in other clinical contexts indicate that TXA has
promise in the prevention of PPH. Nevertheless, the
available evidence from RCTs is of insufficient quality to
reach any definitive conclusion, although it does suggest
that TXA administration reduces postpartum blood loss.
We hope that the issue of TXA for the prevention of
PPH following a vaginal delivery will be informed by the
results of this large, adequately powered, multicenter,
randomized placebo-controlled trial.
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